SNT Syntara Limited

—Mkt Cap: —P/E: —

Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions…

Key Statistics

Company
Market Cap—
Enterprise Value20.46M USD
Revenue (TTM)4.79M USD
Gross Profit-310.99K USD
Net Income (TTM)-6.64M USD
Revenue/Share0.0040 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryDrug Manufacturers - General
ISINAU0000312480
Valuation
P/E (Trailing)—
P/E (Forward)-7.00
PEG2.49
EV/EBITDA-3.11
EV/Revenue4.27
P/S5.95
P/B2.62
EPS (TTM)-0.01
EPS (Forward)-0.00
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-6.49%
Oper. Margin-95.99%
EBITDA Margin-137.51%
Profit Margin-129.78%
ROE-59.65%
ROA-29.81%
Growth
Revenue Growth-13.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.76M USD
CapEx (TTM)—
FCF Margin-96.74%
FCF Yield—
Net Debt-9.37M USD
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.01
Current Ratio6.57
Quick Ratio6.42
Book Value/Sh0.0080 AUD
Cash/Share0.0070 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.1050 AUD
Target Range0.0600 AUD – 0.1500 AUD
# Analysts2
Ownership
Shares Out.1.96B
Float1.53B
Insiders27.40%
Institutions15.29%
Technical
SMA 500.0246 AUD
SMA 2000.0277 AUD
Beta0.24
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)2.88M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—